Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market
Here is a list of stocks that have fallen in the small and mid-cap carnage despite reporting robust numbers
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Private portfolio manager Vivek Pandey is backing Wockhardt thanks to its long ANDA pipeline